Versant Capital Management, Inc Syndax Pharmaceuticals Inc Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 822 shares of SNDX stock, worth $7,948. This represents 0.0% of its overall portfolio holdings.
Number of Shares
822Holding current value
$7,948% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$82.4 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$76.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$47.1 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$40.7 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$38.8 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $547M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...